Trending: Merck to Acquire Imago BioSciences for $1.35 Billion
November 21 2022 - 2:35PM
Dow Jones News
14:05 ET -- Merck & Co. Inc. is one of the most talked about
companies in the U.S. across all news items in the last 12 hours,
according to Factiva data. Merck said it would acquire Imago
BioSciences Inc. for $36 a share in cash for a total purchase price
of about $1.35 billion. Imago is a clinical-stage biopharmaceutical
company developing new medicines for myeloproliferative neoplasms
and other bone marrow diseases. "This acquisition of Imago augments
our pipeline and strengthens our presence in the growing field of
hematology," said Robert Davis, Merck's president and chief
executive officer. Dow Jones & Co. owns Factiva.
(jennifer.tershak@wsj.com)
(END) Dow Jones Newswires
November 21, 2022 14:20 ET (19:20 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Imago BioSciences (NASDAQ:IMGO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Imago BioSciences (NASDAQ:IMGO)
Historical Stock Chart
From Dec 2023 to Dec 2024
